Gastrointestinal Drugs Market Insights & Size Outlook 2027

Gastrointestinal Drugs Market Forecast to 2027 - Global Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, Others); Route of Administration (Oral, Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

  • Report Code : TIPRE00014758
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 211
Buy Now

The gastrointestinal drugs market size is expected to grow from US$ 49,043.38 million in 2019 to US$ 71,300.28 million by 2027; it is estimated to record a CAGR of 4.9% from 2020 to 2027.

Analyst Perspective

Rising investments in the development of biologics and the emergence of a biosimilar are expected to grow at a lucrative rate over the forecast period. Pharmaceutical companies are investing in research and development to discover new and improved gastrointestinal drugs. These are improved gastrointestinal drugs and these advancements have led to the introduction of innovative medications with enhanced efficacy, improved tolerability, and fewer side effects. Newer drugs options provide healthcare providers with more treatment choices and better outcomes for patients. There has been an improvement in medical awareness and diagnostic techniques for gastrointestinal disorder. This has led to earlier and more accurate diagnosis, prompting healthcare providers to prescribe appropriate medications for treatment. With increased awareness among patients, there is also a higher demand for effective drugs to alleviate symptoms and improve quality of life. Additionally, the presence of highly advanced medical care facilities and high healthcare expenditure are boosting the gastrointestinal drugs market growth in various regions.

Market Overview

Gastrointestinal drugs are a category of medications that are used to treat disorders and conditions related to the gastrointestinal system, which includes the organs involved in digestion, absorption, and elimination of food and waste. Various factors can contribute to GI disorder, including infections, inflammation, acid secretion imbalances, ulcers, and other structural abnormalities. Some gastrointestinal disorders involve abnormal mobility, which affects the movement of food through the digestive tract. Drugs that enhance or regulate motility, such as prokinetic agents, can be used to treat conditions like gastroparesis or irritable bowel syndrome (IBS). Also, growing incidences of chronic constipation among all age groups, increasing over-the-counter sales, increasing demand for laxatives, and increasing product offerings from manufacturers contributes to the growth of the gastrointestinal drugs market.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Gastrointestinal Drugs Market: Strategic Insights

Gastrointestinal Drugs Market

  • CAGR (2019 - 2027)
    5.4%
  • Market Size 2019
    US$ 49.04 Billion
  • Market Size 2027
    US$ 71.3 Billion

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • Sanofi
  • GlaxoSmithKline plc
  • Johnson and Johnson Services, Inc.
  • Bausch Health
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Bayer AG
  • Celltrion Healthcare Co.,Ltd

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Drug Class
  • Acid Neutralizers
  • Antidiarrheal and Laxatives
  • Anti-Inflammatory Drugs
  • Antiemetic and Antinauseants
  • Biologics
  • Others
Route of Administration
  • Oral
  • Parenteral
Application
  • Inflammatory Ulcerative Colitis
  • Crohn's Disease
  • Irritable Bowel Syndrome
  • Gastroenteritis
  • Celiac Disease
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Driver

Increase in Development of Biologics to Drive Global Gastrointestinal Drugs Market Growth

Increasing development of biologics for the treatment of GI diseases is driving the growth of the market. In the last few years, new treatments called biologics are being used for the treatment of inflammatory diseases.  Currently, the FDA has approved Humira, Cimzia, Remicade, Simponi, Tysabri, and Entyvio biologics for the treatment of Crohn’s disease and ulcerative colitis. Biologics have revolutionized the IBD treatment, and their success in the treatment of these indications is driving the use of biologics in other GI conditions, such as celiac disease, eosinophilic esophagitis, and autoimmune hepatitis. The development of new medication is driving the growth of the market. For instance, in September 2019, Janssen Pharmaceutical received the European Commission approval for STELARA. It will be used in the treatment of moderately to severely active ulcerative colitis in adults. It is the first biologic treatment that will target the IL-12/IL-23 pathway, an important therapeutic target in UC. Apart from this, strategic initiatives by market players, such as product launch in untapped markets, are further driving the growth of the market. For instance, in July 2020, Takeda Pharmaceutical Company launched its blockbuster biologic drug Vedolizumab in India as part of its GI portfolio. Vedolizumab would be sold in India under the brand name Kynteles. It would be used for the treatment of chronic inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease.  The cases of GI disorders are on the rise in developing countries. For instance, there are currently around 1.5 million IBD patients in India. The introduction of new biologics in these markets is expected to drive the market growth during the forecast period.

Moreover, along with product launches, the market players are carrying out different strategies to add innovative therapies in their product portfolio. This is further driving the growth of the gastrointestinal drugs market. For instance, in February 2020, Takeda Pharmaceutical Company Limited acquired PvP Biologics, Inc. This acquisition added investigational medicine TAK-062 (Kuma062) in the company's GI portfolio, which would be used for the treatment of uncontrolled celiac disease. The company is planning to submit data from the Phase 1 study for presentation at an upcoming medical congress. Globally, many people are living with celiac disease, and they manage their symptoms by following a gluten-free diet.  There is still no treatment for people who experience severe symptoms. With this acquisition, the company is expecting to bring new therapies in the area of celiac disease management

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Segmental Analysis

Based on application, the gastrointestinal drugs market is segmented into inflammatory ulcerative colitis, Crohn's disease, irritable bowel syndrome, gastroenteritis, celiac disease, and others. In 2019, the inflammatory ulcerative colitis segment held a larger share of the gastrointestinal drugs market. However, the irritable bowel syndrome segment is anticipated to register the highest CAGR in the gastrointestinal drugs market during the forecast period. The growing prevalence of Ulcerative colitis (UC) is driving the adoption of GI drugs in the forecast period for the gastrointestinal drugs market. As per the study published in NCBI, In the US, 34 children per 100,000 persons have UC, while for adults the prevalence is 263 per 100,000 persons. Also, the growth of this segment can be attributed to easy availability of drugs to treat this condition. In addition, many manufactures have launched a wide range of biologics for UC, which is further driving the growth of the gastrointestinal drugs market. For instance, Takeda Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer are among the top companies that have established themselves in the market with their products for the treatment of inflammatory ulcerative colitis. 

pharmaceuticals
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Regional Analysis

The Asia- Pacific gastrointestinal drugs market was valued at US$ 8,868.44 million in 2019 and is projected to reach US$ 13,618.35 million by 2027; it is expected to grow at a CAGR of 5.6% during the forecast period. The Asia-Pacific gastrointestinal drugs market is segmented into the China, Japan, India, Australia, South Korea and Rest of Asia Pacific. The Japan held the largest share of the Asia-Pacific gastrointestinal drugs market in 2019. The growth of the gastrointestinal drugs market in the country is primarily driven by growing prevalence of gastrointestinal diseases in Japan which is likely to demand gastrointestinal drugs. As per the study ‘Trends in Gastrointestinal Diseases in Japan’, the incidence of gastric cancer is high in East Asian countries, including Japan. It also reported that incidence of gastroesophageal reflux disease (GERD) and IBD is continuously increasing, which will fuel the growth of gastrointestinal drugs market.

Moreover, new product launches and funding for research purposes also drive the gastrointestinal drugs market growth in the US. For instance, In June 2023, Astellas Pharma Inc. announced the submission of a New Drug Application to Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. Thus, above mentioned factors are expected to propel the gastrointestinal drugs market growth in the Asia-Pacific region.

Key Player Analysis

The gastrointestinal drugs market analysis consists of players, such as Sanofi, GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Bausch Health, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Celltrion Healthcare Co.,Ltd., and LEXICON PHARMACEUTICALS, INC, among others are the top two players owing to the diversified product portfolio offered.

Recent Developments

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the gastrointestinal drugs market. A few recent key market developments in the gastrointestinal drugs market are listed below: 

  • In July 2020, Celltrion Healthcare received marketing authorization approval the European Commission (EC) for Remsima (infliximab, CT-P13). It is a subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis.
  • In May 2020, Sanofi a leading manufacturer of brands such as Buscopan for irritable Bowel Syndrome and Dulcolax for constipation relief has entered into the digestive wellbeing market space with the launch of a new food supplement, Buscobiota. Buscobiota comprised of three types of Lactobacillus and two types of Bifidobacterium which can be used as a preventive medication for chronic constipation.

Gastrointestinal Drugs Market Report Scope

Report Attribute Details
Market size in 2019 US$ 49.04 Billion
Market Size by 2027 US$ 71.3 Billion
Global CAGR (2019 - 2027) 5.4%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Drug Class
  • Acid Neutralizers
  • Antidiarrheal and Laxatives
  • Anti-Inflammatory Drugs
  • Antiemetic and Antinauseants
  • Biologics
  • Others
By Route of Administration
  • Oral
  • Parenteral
By Application
  • Inflammatory Ulcerative Colitis
  • Crohn's Disease
  • Irritable Bowel Syndrome
  • Gastroenteritis
  • Celiac Disease
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Sanofi
  • GlaxoSmithKline plc
  • Johnson and Johnson Services, Inc.
  • Bausch Health
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Bayer AG
  • Celltrion Healthcare Co.,Ltd
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    Drug Class, Route of Administration, Application, and Distribution Channel

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

    Frequently Asked Questions


    What is gastrointestinal drugs?

    Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits globally. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.

    Who are the major players in the gastrointestinal drugs market?

    The gastrointestinal drugsmarket majorly consists of the players such as Sanofi, GlaxoSmithKline plc, Johnson and Johnson Services, Inc., Bausch Health, AstraZeneca, Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Celltrion Healthcare Co., Ltd, and LEXICON PHARMACEUTICALS, INC. are among others.

    What are the driving factors for the gastrointestinal drugs market across the globe?

    The factors that are driving growth of the market are rise in prevalence of gastrointestinal (GI) diseases and increase in development of biologics are expected to boost the growth of the global gastrointestinal drugsmarket.

    The List of Companies - Gastrointestinal Drugs Market

    1. Sanofi
    2. GlaxoSmithKline plc
    3. Johnson and Johnson Services, Inc.
    4. Bausch Health
    5. AstraZeneca
    6. Takeda Pharmaceutical Company Limited
    7. AbbVie Inc.
    8. Bayer AG
    9. Celltrion Healthcare Co.,Ltd
    10. LEXICON PHARMACEUTICALS, INC

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • 3.1 Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • 3.2 Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • 3.3 Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • 3.4 Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Trends and growth analysis reports related to Gastrointestinal Drugs Market